Highbridge Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Highbridge Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-50,266	Closed	-$3.42M	–	1846
2017 Q4	$3.42M	Buy	50,266 +266	+0.5%	+$18.6K	0.06%	311
2017 Q3	$4.12M	Buy	50,000 +39,200	+363%	+$3.11M	0.06%	326
2017 Q2	$1.01M	Sell	10,800 -1,069	-9%	-$65.4K	0.02%	568
2017 Q1	$755K	Buy	11,869 +1,869	+19%	+$114K	0.01%	730
2016 Q4	$444K	Sell	10,000 -2,015	-17%	-$70.9K	0.01%	812
2016 Q3	$433K	Buy	+12,015	New	+$258K	0.01%	848
2016 Q2	–	Sell	-11,057	Closed	-$212K	–	1843
2016 Q1	$212K	Buy	+11,057	New	+$234K	﹤0.01%	1317

Other funds holding CLVS

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Highbridge Capital Management's CLVS Position: Q1 2018 in Review

Highbridge Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2018, closing a stake of 50,266 shares — an estimated $3.42M sold.

Highbridge Capital Management first reported a position in CLVS in Q1 2016 and held it in 7 quarters. The position peaked at $4.12M in Q3 2017. 229 funds tracked by Wall St. Rank hold CLVS as of Q1 2018.

Highbridge Capital Management reported no remaining Clovis Oncology, Inc. position as of Q1 2018 after selling out during the quarter.
Highbridge Capital Management sold 50,266 Clovis Oncology, Inc. shares in Q1 2018, an estimated $3.42M.
Highbridge Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2016 and held it in 7 quarters.
Highbridge Capital Management's Clovis Oncology, Inc. position peaked at $4.12M in Q3 2017.
229 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2018.

Based on Highbridge Capital Management's 13F filing for Q1 2018, filed 15 May 2018.